**** inhibitor substance-based systemic lupus erythematosus new drug candidate substance development

PROVIBIO

PROVIBIO
ProviBio co., LTD.

IMMUNOLOGY | **Candidate**

Product Type	Small molecules
Indication	Systemic lupus erythematosus (SLE)
Target	**** inhibitor
MoA(Mechanism of Action)	• Targeting the **** inhibitor • ATP non-competitive inhibitory mechanism • Suppression of the PI3K signaling pathway • Reduction of p-AKT and p-mTOR signaling • Inhibition of T/B cell activation • Suppression of plasma cell differentiation and autoantibody production • Reduction of inflammatory cytokine production
Competitiveness	• Selective immunomodulation compared with conventional steroids and immunosuppressants • Superior kinase selectivity compared with ATP-competitive inhibitors • Potential reduction of off-target toxicity • Demonstrated efficacy in cellular and lupus mouse models • Reduction of proteinuria, anti-dsDNA, and total IgG levels • Expandable platform pipeline for immune disorders and oncology
Development Stage	Candidate
Route of Administration	• PO(Oral administration)